The comment period closed
On July 30 the public comment window shut on an FDA proposal that would formally close the largest bulk-compounding route for GLP-1 medications. Nothing is final. But if your prescription is compounded, this is the month to find out how yours is actually made.
A note on what this is
This is a plain-language read of a regulatory process, written by people who follow it closely because our readers are affected by it. It is not legal advice, not medical advice, and not a prediction. Nobody knows how this lands. What we can do is make sure you are not the last to hear about it.
Start with the part that is easy to miss: nothing has been decided.
In May the FDA proposed not to add semaglutide, tirzepatide, and liraglutide to what is called the 503B Bulks List — the roster of bulk drug substances that large outsourcing facilities are permitted to compound from. The agency's stated reasoning was that the evidence did not establish a clinical need. The public comment window ran through the end of July. It is now closed. There is no final rule, no effective date, and no announcement about when either arrives.
So this is not the sky falling. It is a door being slowly pulled toward its frame, in public, with a lot of people shouting from both sides.
The distinction almost nobody explains
Here is the piece that decides whether any of this touches you personally, and it took us longer than it should have to get a straight answer on it.
There are two compounding pathways, and they are not the same thing. A 503B outsourcing facility makes medication in bulk, in advance, without a name attached — the model that made large-scale telehealth GLP-1 programs possible. A 503A pharmacy compounds against a prescription written for one identified patient. The proposal on the table is about the 503B bulks list. It is not, on its face, the same as ending 503A compounding.
That is why the pharmacy line on every scorecard in our comparison is not decoration. If a provider tells you nothing about where or how your medication is made, that silence is now a piece of information.
"Compounded" is not one thing. Which pathway your prescription runs through is the difference between a policy story and your policy story.
How we got here, briefly
The legal ground under large-scale compounding was always the shortage. When a drug is in shortage, compounding it is permitted in ways it otherwise is not. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, and the enforcement grace period that followed has since ended.
Then came the letters. The agency has issued well over a hundred warning letters to telehealth companies and compounders over false or misleading marketing, including a batch to roughly thirty firms specifically about claiming compounded products were "identical" to the branded ones. They are not. Separately, both manufacturers have been litigating against distributors since 2025, and at least one suit has alleged serious impurity levels in tested product.
We report that plainly because we think you can hold two things at once: that compounded medication has been a genuine lifeline for women priced out of branded GLP-1s, and that the quality floor across the market has been uneven enough to justify scrutiny. Both are true. Neither cancels the other.
What this has to do with PMOS (PCOS) and endometriosis
Directly, not much. Indirectly, a great deal.
Women in this readership are disproportionately paying cash. Insurance coverage for a GLP-1 tends to hinge on a diabetes diagnosis or a BMI threshold, and a woman with PMOS (PCOS) whose central problem is insulin resistance often satisfies neither on paper. Compounded medication has been the affordable path for exactly that gap. If that path narrows, the people who feel it first are the ones who were already being told their condition did not qualify.
For readers with endometriosis, we will say what we always say: a GLP-1 is not a treatment for endo, and no regulatory outcome changes that. What endo does change is the standard you should hold a provider to. If a clinician has already shown you they will read your full gynecologic picture rather than dismissing it, that is also the clinician most likely to handle a supply disruption without leaving you to improvise. Continuity of care is not a separate issue from good care. It is the same issue, viewed later.
Five questions worth asking this month
Not to panic. To be ahead of it.
Is my medication compounded, and through a 503A pharmacy or a 503B outsourcing facility? A provider who cannot answer that quickly has told you something.
If compounded access changed, what would you move me to? The answer should be a specific plan, not reassurance.
Would I keep my current dose in that transition, or restart titration? This is the question that most affects how the next few months feel.
Am I on a prepaid multi-month plan, and what happens to that money if supply changes? Several plans in our comparison require three-, six-, or twelve-month commitments to reach their advertised price. Read those terms now, not later.
Is there a maintenance or off-ramp protocol, and is it written down? The whole point of an off-ramp is that it exists before you need one.
What we are doing
Watching the docket and updating the comparison when facts move, not when headlines do. If a final rule issues, we will rewrite what needs rewriting and say plainly what changed. If it does not, we will say that too — quietly, without inventing an emergency to justify a post.
In the meantime the advice is unglamorous and unchanged: know how your medication is made, know what your provider's plan B is, and read the cancellation terms before you need them.
The honest disclaimer. This is general information from the women who write Selene — not medical, legal, or regulatory advice, and not a forecast of any agency decision. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. No GLP-1 is FDA-approved specifically for PMOS (PCOS), and GLP-1 medications are not a treatment for endometriosis. Regulatory status and provider terms change; confirm both directly. Selene is editorial: we do not prescribe, sell, or dispense anything.